(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 18.59% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.41%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.1%.
Supernus Pharmaceuticals's revenue in 2026 is $718,952,000.On average, 8 Wall Street analysts forecast SUPN's revenue for 2026 to be $50,642,539,887, with the lowest SUPN revenue forecast at $48,259,232,827, and the highest SUPN revenue forecast at $52,703,965,176. On average, 8 Wall Street analysts forecast SUPN's revenue for 2027 to be $60,230,470,752, with the lowest SUPN revenue forecast at $56,689,771,281, and the highest SUPN revenue forecast at $63,742,955,184.
In 2028, SUPN is forecast to generate $68,867,727,552 in revenue, with the lowest revenue forecast at $63,339,883,200 and the highest revenue forecast at $73,359,101,088.